GLP-1 drugs have picked up another flattering association, this time in the operating theatre. Research presented at the ANESTHESIOLOGY 2026 annual meeting found that adults taking the medications had lower rates of serious heart-related complications and infections after surgery than comparable patients who were not on them.
The study was large enough to quiet the usual “small sample” shrug. Researchers examined records from 2,028,601 U.S. adults in the Epic Cosmos electronic health record database, covering patients age 18 and older who underwent elective surgeries lasting more than 60 minutes and stayed in hospital for at least 24 hours between January 2016 and December 2024. About 145,610 patients, roughly 7%, were taking GLP-1 medications.
After matching GLP-1 users with similar non-users, the researchers found GLP-1 use was associated with 11% lower odds of major cardiovascular complications, including heart attack, heart injury, stroke or death. It was also associated with 8% lower odds of postoperative infections such as surgical-site infections, urinary tract infections, pneumonia and sepsis.
That matters because GLP-1s are already culturally overexposed and clinically everywhere, prescribed for diabetes and weight loss and discussed with the fervour usually reserved for a prestige handbag or a scandalous casting decision. Surgery, though, is less interested in hype than in what keeps a patient stable under stress. The question here is not whether the drugs are fashionable, but whether they help when the body is pushed into one of its least glamorous states.
Josephine Tolan, an anesthesiologist at McGovern Medical School at UTHealth Houston and the study’s lead author, said physicians still need more evidence about how GLP-1 medications affect patients around the time of surgery. She called the results encouraging, while stressing that more research is needed to determine whether the drugs themselves are driving the benefits and how they should be managed before and after procedures.
That caution is doing real work. This was an observational study based on existing medical records, not a randomized trial, so it cannot prove cause and effect. Patients taking GLP-1s may differ from non-users in ways the matching process could not fully capture. The authors said possible explanations include better blood sugar control, lower inflammation, weight loss, improved blood pressure and even direct protection of heart muscle during periods of stress. All plausible, none settled.
For now, the finding lands as a reminder that GLP-1s are becoming less a single-purpose drug category than a sprawling medical franchise. Whether that expansion reflects genuine protective effects or the flattering blur that often surrounds blockbuster treatments is exactly what the next round of research will have to sort out.
Sophia Borg 
Harvey Jr. 
Gabriel Fenech